Adoptive immunotherapy (AI) of cancer, based upon injection of in vitro manipulated autologous lymphocytes is still in an experimental phase. Based on strong experimental and pre-clinical rationale, our group started different clinical trials of AI in early 1990, and a number of patients with solid tumors (melanoma, kidney carcinoma, non-small-cell lung cancer, mesothelioma, neoplastic pleural effusion, and liver cancer) were treated with either locoregional or systemic adoptive immunotherapy using both LAK and TIL cells in combination with s.c. rIL-2. The surgery/AI combination resulted. in good clinical results, characterized by enhanced. survival and long lasting disease free periods in a significant number of patients. Nevertheless, at present, new preclinical evidences and strategies are needed to enhance the efficacy of the adoptive immunotherapy approach of solid tumor treatment.
|Number of pages||7|
|Publication status||Published - Dec 1999|
- Carcinoma, non-small-cell lung/therapy Immunotherapy, adoptive
- Interleukin-2/administration and dosage
- Lymphocytes, tumor-infiltrating, immunology
ASJC Scopus subject areas
- Applied Microbiology and Biotechnology